StockDuty ← Dashboard Oct 27, 2026 07:00 PM ET
SignalCorporate

Repligen signals at least 25% 2027 top line growth with BioLife, targeting over $1B revenue

Repligen targets over $1B revenue with at least 25% 2027 growth via BioLife.

What changed
Repligen targets over $1B revenue with at least 25% 2027 growth via BioLife.
Why it matters
Repligen targets over $1B revenue with at least 25% 2027 growth via BioLife. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →